Acadian Asset Management LLC Biogen Inc. Transaction History

Acadian Asset Management LLC

$32.5 Billion
Q2 2024

A detailed history of Acadian Asset Management LLC transactions in Biogen Inc. stock. As of the latest transaction made, Acadian Asset Management LLC holds 5,702 shares of BIIB stock, worth $990,950. This represents 0.0% of its overall portfolio holdings.

Number of Shares

5,702

Previous 1,889 201.85%

Holding current value

$990,950

Previous $407,000 224.32%

% of portfolio

0.0%

Previous 0.0%

27 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 06, 2024	BUY	$190.52 - $236.72 $726,452 - $902,613	3,813 Added 201.85%	5,702 $1.32 Million
Q1 2024 May 10, 2024	SELL	$212.02 - $267.71 $8,056 - $10,172	-38 Reduced 1.97%	1,889 $407,000
Q4 2023 Feb 13, 2024	SELL	$222.59 - $267.94 $2.54 Million - $3.05 Million	-11,398 Reduced 85.54%	1,927 $497,000
Q3 2023 Nov 13, 2023	SELL	$253.3 - $285.89 $8.29 Million - $9.35 Million	-32,715 Reduced 71.06%	13,325 $3.42 Million
Q2 2023 Aug 07, 2023	BUY	$275.25 - $318.06 $104,870 - $121,180	381 Added 0.83%	46,040 $13.1 Million
Q1 2023 May 11, 2023	SELL	$256.56 - $292.34 $3.58 Million - $4.08 Million	-13,962 Reduced 23.42%	45,659 $12.7 Million
Q4 2022 Feb 14, 2023	SELL	$252.44 - $306.72 $8.16 Million - $9.92 Million	-32,332 Reduced 35.16%	59,621 $16.5 Million
Q3 2022 Nov 14, 2022	BUY	$194.69 - $268.46 $3.29 Million - $4.53 Million	16,878 Added 22.48%	91,953 $24.5 Million
Q3 2022 Nov 14, 2022	BUY	$194.69 - $268.46 $3.29 Million - $4.53 Million	16,878 Added 22.48%	91,953 $24.5 Million
Q2 2022 Aug 09, 2022	SELL	$187.54 - $223.02 $7.4 Million - $8.8 Million	-39,465 Reduced 34.46%	75,075 $15.3 Million
Q1 2022 May 12, 2022	BUY	$193.77 - $244.14 $16.8 Million - $21.2 Million	86,746 Added 312.1%	114,540 $24.1 Million
Q4 2021 Feb 10, 2022	SELL	$223.92 - $287.77 $9.71 Million - $12.5 Million	-43,381 Reduced 60.95%	27,794 $6.67 Million
Q3 2021 Nov 12, 2021	SELL	$282.99 - $369.05 $30.6 Million - $39.9 Million	-108,046 Reduced 60.29%	71,175 $20.1 Million
Q2 2021 Aug 11, 2021	SELL	$259.0 - $414.71 $44.4 Million - $71.1 Million	-171,511 Reduced 48.9%	179,221 $62.1 Million
Q1 2021 May 11, 2021	SELL	$242.95 - $284.63 $37 Million - $43.4 Million	-152,468 Reduced 30.3%	350,732 $98.1 Million
Q4 2020 Feb 11, 2021	SELL	$236.26 - $355.63 $4.99 Million - $7.51 Million	-21,114 Reduced 4.03%	503,200 $123 Million
Q3 2020 Nov 09, 2020	BUY	$264.77 - $305.71 $37.1 Million - $42.8 Million	140,012 Added 36.43%	524,314 $149 Million
Q2 2020 Aug 12, 2020	BUY	$258.66 - $342.55 $77.6 Million - $103 Million	299,950 Added 355.59%	384,302 $103 Million
Q1 2020 May 11, 2020	BUY	$268.85 - $341.04 $21.9 Million - $27.8 Million	81,577 Added 2939.71%	84,352 $26.7 Million
Q3 2019 Nov 07, 2019	SELL	$217.44 - $243.88 $246,576 - $276,559	-1,134 Reduced 29.01%	2,775 $646,000
Q1 2019 May 09, 2019	SELL	$216.71 - $338.96 $2.01 Million - $3.14 Million	-9,252 Reduced 70.3%	3,909 $924,000
Q4 2018 Feb 07, 2019	SELL	$278.5 - $352.75 $30.4 Million - $38.5 Million	-109,257 Reduced 89.25%	13,161 $3.96 Million
Q3 2018 Oct 30, 2018	BUY	$293.51 - $383.83 $34.4 Million - $44.9 Million	117,069 Added 2188.61%	122,418 $43.3 Million
Q2 2018 Jul 24, 2018	SELL	$257.52 - $306.91 $3.16 Million - $3.77 Million	-12,279 Reduced 69.66%	5,349 $1.55 Million
Q1 2018 Apr 12, 2018	BUY	$260.13 - $367.91 $2.14 Million - $3.03 Million	8,243 Added 87.83%	17,628 $4.83 Million
Q4 2017 Jan 18, 2018	BUY	$307.64 - $344.58 $741,104 - $830,093	2,409 Added 34.53%	9,385 $2.99 Million
Q3 2017 Oct 13, 2017	BUY	$281.15 - $329.69 $1.96 Million - $2.3 Million	6,976	6,976 $2.19 Million

Others Institutions Holding BIIB

# of Institutions

1,018

Shares Held

128M

Call Options Held

1.22M

Put Options Held

1.4M

View Full List

About BIOGEN INC.

Ticker BIIB
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 144,000,992
Market Cap $25B
Description
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...

More about BIIB

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Acadian Asset Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Acadian Asset Management LLC with notifications on news.

Account

Acadian Asset Management LLC Biogen Inc. Transaction History